Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Iressa/Docetaxel in Non-Small-Cell Lung Cancer
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00048087
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
- Conditions
- First Posted Date
- 2002-10-24
- Last Posted Date
- 2016-08-25
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 129
- Registration Number
- NCT00047840
- Locations
- 🇭🇺
Research Site, Torokbalint, Hungary
ASCENT: Androgen Independent Prostate Cancer Study of Calcitriol Enhancing Taxotere
- Conditions
- First Posted Date
- 2002-08-13
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Novacea
- Target Recruit Count
- 250
- Registration Number
- NCT00043576
- Locations
- 🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Texas Oncology, P.A., Dallas, Texas, United States
🇺🇸Kaiser- Northern California, Vallejo, California, United States
Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT00038194
- Locations
- 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States
Ketoconazole Plus Docetaxel to Treat Prostate Cancer
- Conditions
- First Posted Date
- 2002-04-04
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 674
- Registration Number
- NCT00032825
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.